Tags : Avelumab

Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in

Shots: The P-III JAVELIN Bladder 100 study involves assessing of Bavencio + best supportive care (BSC) vs BSC monothx in 700 patients with LA or mUC whose disease did not progress after completion of 1L Pt-chemotherapy The study resulted in improvement in OS with consistent safety results and will be shared with the US FDA […]Read More

Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer

Shots: Tilt initiates the collaboration with Merck KGaA & Pfizer to evaluate TILT-123 with avelumab in patients with solid tumors refractory to routine modalities TILT-123 will evaluate for solid tumors in the US & Europe and preclinical results of the dual combination, TILT technology and anti-PDL1 agent demonstrated immune activation & efficacy Bavencio (avelumab) is […]Read More

Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in

Shots: The P-III JAVELIN Renal 101 trial involves assessing of Bavencio (avelumab) + Inlyta (axitinib) vs Sutent (sunitinib) in 886 patients with previously untreated advanced RCC P-III JAVELIN Renal 101 trial results: mPFS (13.8 mos. vs 7.2 mos.); ORR (51.4% vs 25.7%); 39% reduction in risk of disease progression; received anticancer drug therapies (20.8% vs […]Read More

Merck and Pfizer Reports Results of Avelumab in P-III JAVELIN

Shots: The P-III JAVELIN Ovarian 100 study involves assessing of avelumab + and/or following Pt-based carboplatin/paclitaxel CT in 998 patients with LA or metastatic (Stage III or Stage IV) epithelial ovarian cancer, fallopian tube cancer (FTC), or primary peritoneal cancer The study resulted in unmet 1EPs as PFS and has shown no new safety signals with consistent safety profile […]Read More